Your industry news - first Number 1 for Recruitment
We strongly recommend viewing Cleanzine full size in your web browser. Click our masthead above to visit our website version.
With perfect timing, Swiss-based Lonza issues guidance on controlling Ebola spread
Lonza, the Basel, Switzerland-based, global manufacturer of disinfectants and disinfectant cleaners, is offering guidance on the use of its portfolio of products as part of an infection control programme for the Ebola virus.
On 1st August 2014, the US Centers for Disease Control and Prevention released guidance titled 'Infection Prevention and Control Recommendations for Hospitalized Patients with Known or Suspected Ebola Hemorrhagic Fever in US Hospitals.'
The CDC states in part: "Ebola viruses are transmitted through direct contact with blood or body fluids/substances (e.g., urine, faeces, vomit) of an infected person with symptoms or through exposure to objects (such as needles) that have been contaminated with infected blood or body fluids. The role of the environment in transmission has not been established".
It continues to say that, as part of the programme of care of persons with probable or confirmed Ebola virus infections, hospitals are recommended to "use a U.S. Environmental Protection Agency (EPA)-registered hospital disinfectant with a label claim for a non-enveloped virus (e.g., norovirus, rotavirus, adenovirus, poliovirus) to disinfect environmental surfaces in rooms of patients with suspected or confirmed Ebola virus infection."
Separately, and in specific reference to "Environmental infection control", the CDC has stated "Appropriate disinfectants for Ebola virus and other filoviruses include...hospital-grade quaternary ammonium...products."
In addition, within Europe, the current EN 14885:2006 standard 'Application of European Standards for Chemical Disinfectants and Antiseptics' stipulates that for a 'virucidal' claim to be made for hard surface and instrument disinfectants, efficacy against poliovirus and adenovirus needs to be demonstrated using the EN 14476:2005 test protocol.
Many of Lonza's products have supported label claims for viruses including those identified by US CDC and within EN 14885:2006 and the manufacturer offers for sale disinfectants with specific claims against target organisms as approved for the jurisdiction in which each product is sold.
Available within Lonza's US portfolio are several product families that meet the CDC guidance to use products having efficacy against non-enveloped viruses including Bardac 205M, Lonzagard HWS, Lonzagard R-82, Lonzagard RCS and Lonzagard Disinfectant Wipes. In Europe, Lonzagard DR-25aN Disinfectant Cleaner can make 'virucidal' claims according to standards set by EN 14885:2006.
Lonza also offers HTH Calcium Hypochlorite, a multi-purpose disinfectant and sanitiser. Chlorine products are widely recognised and recommended by international health authorities and used by non-governmental organisations. HTH Calcium Hypochlorite has been registered for the sanitation of drinking and waste water and for the disinfection of hard surfaces, vehicles and containers, among other uses.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013.
NAFTA - [email protected] - +1 678 442 1001
EMEA - [email protected] - +44 161 721 2023
Japan - [email protected] / [email protected] - +81 3 6264 0600
Japan - [email protected] - +81 3 6264 0600
China - [email protected] - +86 21 63403488 (Ext. 5871)
South East Asia - [email protected] - +65 6521 4364
Latin America - [email protected] - +55 11 4501 1226
India [email protected] - +91 22 4342 4017
23rd October 2014